TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($3.13), $1.09 worse than the analyst estimate of ($2.04). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $30.2 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.